Announces The Co And Its CLIA Laboratory Partner Have Submitted An Application To The American Medical Association CPT Editorial Panel Requesting The Assignment Of A Proprietary Laboratory Analysis Code For The InFoods IBS Diagnostic Test

- Application represents milestone toward broadening patient access to inFoods IBS

- inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation

IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test. If granted, the PLA code will provide a test-specific code to submit claims to Medicare and other insurers. The PLA code would represent a next step on the pathway to expand patient access to the inFoods IBS product, a personalized test and therapy for treating Irritable Bowel Syndrome (IBS).